Literature DB >> 22403261

High community faecal carriage rates of CTX-M ESBL-producing Escherichia coli in a specific population group in Birmingham, UK.

Nimal H Wickramasinghe1, Li Xu, Andrew Eustace, Sahida Shabir, Tranprit Saluja, Peter M Hawkey.   

Abstract

OBJECTIVES: To determine the proportion of E. coli carrying specific CTX-M extended-spectrum β-lactamase (ESBL) genotypes in a community population of East and North Birmingham.
METHODS: General practice and outpatient stool samples from 732 individuals submitted for examination for faecal pathogens in 2010 were screened for ESBL-producing E. coli using chromogenic agar. Multiplex PCR, denaturing HPLC, DNA sequencing and PFGE were used to determine the CTX-M genotype and clonal subtype. Isolates from people were assigned to 'Europe', 'Middle East/South Asia' (MESA) or 'uncategorized' groups using software to determine probable global origin based on the subject's full name.
RESULTS: Prevalence of CTX-M carriage in the sample population was 11.3%. There was a statistically significant difference (P < 0.001) between carriage in the Europe group (8.1%) and the MESA group (22.8%). There was also a higher rate of carriage of CTX-M-15-producing E. coli (P < 0.001) in MESA subjects.
CONCLUSIONS: The high community carriage rate and the significant difference in carriage between the Europe and MESA subjects may have important consequences for therapy. If the rising trend in carriage of bacteria producing ESBLs continues, guidelines for empirical therapy for patients presenting from the community may need to be modified. The findings also raise the concern that the pattern and routes of spread of CTX-M-15 may be replicated in the future by broader-spectrum β-lactamases, such as New Delhi metallo-β-lactamase ('NDM-1').

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22403261     DOI: 10.1093/jac/dks018

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

1.  Is fecal carriage of extended-spectrum-β-lactamase-producing Escherichia coli in urban rats a risk for public health?

Authors:  Sebastian Guenther; Julia Wuttke; Astrid Bethe; Jirí Vojtech; Katharina Schaufler; Torsten Semmler; Rainer G Ulrich; Lothar H Wieler; Christa Ewers
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

2.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

Review 3.  A systematic review and meta-analysis on the prevalence of Escherichia coli and extended-spectrum β-lactamase-producing Escherichia coli in pregnant women.

Authors:  Yousef Moradi; Babak Eshrati; Seyed Abbas Motevalian; Ali Majidpour; Hamid Reza Baradaran
Journal:  Arch Gynecol Obstet       Date:  2021-01-02       Impact factor: 2.344

Review 4.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

5.  Extended-spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community.

Authors:  Giuseppe Valenza; Silke Nickel; Yvonne Pfeifer; Christoph Eller; Elzbieta Krupa; Verena Lehner-Reindl; Christiane Höller
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

6.  An abbreviated MLVA identifies Escherichia coli ST131 as the major extended-spectrum β-lactamase-producing lineage in the Copenhagen area.

Authors:  J B Nielsen; A Albayati; R L Jørgensen; K H Hansen; B Lundgren; K Schønning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-06       Impact factor: 3.267

7.  Emergence and spread of O16-ST131 and O25b-ST131 clones among faecal CTX-M-producing Escherichia coli in healthy individuals in Hunan Province, China.

Authors:  Yi-Ming Zhong; Wen-En Liu; Xiang-Hui Liang; Yan-Ming Li; Zi-Juan Jian; Peter M Hawkey
Journal:  J Antimicrob Chemother       Date:  2015-05-09       Impact factor: 5.790

8.  Fecal carriage of ESBL-producing E. coli and K. pneumoniae in children in Guinea-Bissau: a hospital-based cross-sectional study.

Authors:  Joakim Isendahl; Agata Turlej-Rogacka; Cristovão Manjuba; Amabelia Rodrigues; Christian G Giske; Pontus Nauclér
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  Faecal carriage of extended-spectrum β-lactamase (ESBL)-producing enterobacteria in liver disease patients from two hospitals in Egypt and France: a comparative epidemiological study.

Authors:  N S Fam; S Defasque; F Bert; V Leflon-Guibout; A El-Ray; M El-Ghannam; M E Attia; M Omar; D G Desouki; D Valla; M-H Nicolas-Chanoine
Journal:  Epidemiol Infect       Date:  2014-07-18       Impact factor: 4.434

10.  Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia Coli. an exploratory case-control study.

Authors:  Rasmus Leistner; Elisabeth Meyer; Petra Gastmeier; Yvonne Pfeifer; Christoph Eller; Petra Dem; Frank Schwab
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.